Skip to content
value.today
Adagio Therapeutics, Inc. logo

Adagio Therapeutics, Inc.

🇺🇸 Waltham, Massachusetts, USABiotechnologyFounded 2020
Total raised
$465 M
3 rounds on record
Latest round
$336 M
Apr 2021
First round on record
Jul 2020
Today
Went public
See the company page

Adagio Therapeutics, Inc. is listed today as Invivyd, Inc.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Adagio Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2022$24 MPrivate placement after listing$10 to $50 million

Adagio Therapeutics, Inc.: Private sale, Nov 2022

Investors in this round

1 investor had bought by the notice of Nov 29, 2022: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$24 M of $24 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Hering · Executive Officer, Director · Chief Executive Officer and Director
  • Ellie Hershberger · Executive Officer · Chief Development Officer
  • Fred Driscoll · Executive Officer · Interim Chief Financial Officer
  • Jill Andersen · Executive Officer · Chief Legal Officer and Corporate Secretary
  • Rebecca Dabora · Executive Officer · Chief Technology and Manufacturing Officer
  • Christine A. Lindenboom · Director
  • Clive A. Meanwell · Director
  • Marc Elia · Director · Director, Chair of the Board
  • Michael S. Wyzga · Director
  • Tamsin Berry · Director
  • Terry McGuire · Director
  • Tom Heyman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “See Form 8-K filed by Issuer on 11-17-22 for more details. The Issuer issued a warrant to purchase up to an aggregate of 6,824,712 common shares at an exercise price of $3.48 per share, which may vest in up to three separate tranches.”

Signed by Jill Andersen, Chief Legal Officer and Corporate Secretary. Newest notice filed Nov 29, 2022. Read the notice at the SEC.

equity, optionsSEC
Apr 2021$336 MNo. 3$250 million to $1 billion

Adagio Therapeutics, Inc.: Raise no. 3, Apr 2021

Investors in this round

36 investors had bought by the notice of Apr 30, 2021: 36 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$336 M of $336 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ellie U. Hershberger · Executive Officer
  • Eric U. Kimble · Executive Officer
  • Halley U. Gilbert · Executive Officer
  • Jane U. Henderson · Executive Officer
  • Laura U. Walker · Executive Officer
  • Lynn U. Connolly · Executive Officer
  • Rebecca U. Dabora · Executive Officer
  • Tillman U. Gerngross · Executive Officer, Director
  • Ajay U. Royan · Director
  • Howard U. Mayer · Director
  • Philip U. Chase · Director
  • Rene U. Russo · Director
  • Terrance U. McGuire · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Tillman U. Gerngross, President and Chief Executive Officer. Newest notice filed Apr 30, 2021. Read the notice at the SEC.

equitySEC
Oct 2020$80 MNo. 2$50 to $250 million

Adagio Therapeutics, Inc.: Raise no. 2, Oct 2020

Investors in this round

16 investors had bought by the notice of Nov 12, 2020: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$80 M of $80 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Halley G. Gilbert · Executive Officer
  • Tillman U. Gerngross · Executive Officer, Director
  • Ajay T. Royan · Director
  • Howard G. Mayer · Director
  • Marc G. Elia · Director
  • Philip T. Chase · Director
  • Rene G. Russo · Director
  • Terrance G. McGuire · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Halley Gilbert, Chief Operating Officer and Chief Business Officer. Newest notice filed Nov 12, 2020. Read the notice at the SEC.

equitySEC
Jul 2020$50 MNo. 1$10 to $50 million

Adagio Therapeutics, Inc.: Raise no. 1, Jul 2020

Investors in this round

24 investors had bought by the notice of Nov 12, 2020: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Halley G. Gilbert · Executive Officer
  • Tillman U. Gerngross · Executive Officer, Director
  • Ajay T. Royan · Director
  • Howard G. Mayer · Director
  • Marc G. Elia · Director
  • Philip T. Chase · Director
  • Rene G. Russo · Director
  • Terrance G. McGuire · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Halley Gilbert, Chief Operating Officer and Chief Business Officer. Newest notice filed Nov 12, 2020. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Adagio Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2022).

    SEC Form D · Nov 2022

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2022

Products and services#

No products or services of Adagio Therapeutics, Inc. are on record.

Investors#

No investor of Adagio Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Largest shareholders today

Institutions holding Invivyd, Inc. shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Adagio Therapeutics, Inc.
NameRoleNamed in
David HeringChief Executive Officer and DirectorNov 2022
Ellie HershbergerChief Development OfficerNov 2022
Fred DriscollInterim Chief Financial OfficerNov 2022
Jill AndersenChief Legal Officer and Corporate SecretaryNov 2022
Rebecca DaboraChief Technology and Manufacturing OfficerNov 2022
Ellie U. HershbergerExecutive officerApr 2021
Eric U. KimbleExecutive officerApr 2021
Halley U. GilbertExecutive officerApr 2021
Jane U. HendersonExecutive officerApr 2021
Laura U. WalkerExecutive officerApr 2021
Lynn U. ConnollyExecutive officerApr 2021
Rebecca U. DaboraExecutive officerApr 2021
Tillman U. GerngrossExecutive officerApr 2021
Halley G. GilbertExecutive officerNov 2020
Christine A. LindenboomDirectorNov 2022
Clive A. MeanwellDirectorNov 2022
David HeringChief Executive Officer and DirectorNov 2022
Marc EliaDirector, Chair of the BoardNov 2022
Michael S. WyzgaDirectorNov 2022
Tamsin BerryDirectorNov 2022
Terry McGuireDirectorNov 2022
Tom HeymanDirectorNov 2022
Ajay U. RoyanDirectorApr 2021
Howard U. MayerDirectorApr 2021
Philip U. ChaseDirectorApr 2021
Rene U. RussoDirectorApr 2021
Terrance U. McGuireDirectorApr 2021
Tillman U. GerngrossDirectorApr 2021
Ajay T. RoyanDirectorNov 2020
Howard G. MayerDirectorNov 2020
Marc G. EliaDirectorNov 2020
Philip T. ChaseDirectorNov 2020
Rene G. RussoDirectorNov 2020
Terrance G. McGuireDirectorNov 2020

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.